Presentations and Publications


2018 CommNETs Publications

Click here for: Chan D.L., Moody L., Segelov E., Metz D., Strosberg J., Pavlakis N., Singh S. (2018). “Follow-up for resected gastroenteropancreatic neuroendocrine tumours (GEP-NETs): A practice survey of the Commonwealth Neuroendocrine collaboration (CommNETs) and the North American Neuroendocrine Tumor Society (NANETS).” Neuroendocrinology (accepted for publication), doi:10.1159/000488394.

Click here for: Singh S., Moody L., Chan D.L. Metz D., Strosberg J., Asmis T., Bailey D., Bergsland E., Brendtro K., Carroll R., Cleary S., Kim M., Kong G., Law C., Lawrence B., McEwan S., McGregor C., Michael M., Pasieka J., Pavlakis N., Pommier R., Soulen M., Wyld D., Segelov E. (2018) “Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumours.” JAMA Oncology, doi: doi:10.1001/jamaoncol.2018.2428.

Click here for: Singh S, Chan DL, Moody L, Liu N, Fischer HD, Austin PC, Segelov E. 2018. Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncology. 4:583-585. Impact factor 16.


2017 CommNETs Publications

Click here for: Segelov, E., Chan, D., Lawrence, B., Pavlakis, N., Kennecke, H. F., Jackson, C., et al. (2017). Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration., 3(4), 380–388.


CommNETs Members’ NET Publications

Click here for: Chan D.L., Ferone D., Albertelli M., Segelov E., Singh S. (2017). Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumours (NETs): A systematic Review. Journal of Clinical Oncology, doi: doi/abs/10.1200/JCO.2017.35.4_suppl.422

Click here for: Yao J.C., Fazio N., Singh S., Buzzoni, R., Carnaghi C., Wolin E., Tomasek J., Raderer M., Lahner H., Voi M., Bubuteishvili Pacaud L., Rouyrre N., Sachs C., Valle J.W., Delle Fave G., Can Cutsem E., Tesselaar M., Shimada Y., Oh D., Strosberg J., Kulke M.H., Pavel M.E. (2016). Everolimus for advanced, nonfunctional neuroendocrine tumours of the gastrointestinal tract: Efficacy (RADIANT-4) a randomized, placebo-controlled phase 3 study. The Lancet, doi: https://doi.org/10.1016/S0140-6736(15)00817-X.

Click here for: Singh S., Pavel M.E., Strosberg J.R., Bubuteishvili-Pacaud L., Degtyarev E., Neary M., Hunger M., Eriksson J., Fazio N., Kulke M.H., Yao J.C. (2016). Association of disease progression, health related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumours (NET) in the phase 3 RADIANT-4 trial. Journal of Clinical Oncology, doi: 10.1200/JCO.2016.34.15_suppl.4093.

Click here for: “Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.” Theranostics 7(5): 1149-1158.

Click here for: Chan, D. L. H., et al. (2017). “Prognostic and predictive biomarkers in neuroendocrine tumours.” Crit Rev Oncol Hematol 113: 268-282.


2018 Presentations

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER WORLD CONFERENCE ON LUNG CANCER, SEPTEMBER 23RD -26TH TORONTO, ON, CAN

Click here for: Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus.

NANETs SYMPOSIUM, OCTOBER 4TH-6TH SEATTLE, WA, USA

Click here for: Ontario oncologists’ perspective on addressing potential barriers in the management of patients with neuroendocrine tumors.

Click here for: Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients.

ESMO 2018 CONGRESS OCTOBER 19TH – 23RD 2018, MUNICH GERMANY

Click here for: The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET).

VCCC Survivorship Conference February 8th – 9th | Melbourne, VIC, Australia

Poster Presented by Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) PRRT Working Group.

The challenges of designing and implementing a structured, international multicentre audit on quality of life (QOL) and markers of response in patients with neuroendocrine neoplasms (NEN) treated with peptide receptor radionuclide therapy (PRRT). Poster presented: Click here


Past Presentations

To view all past CommNETs presentations, and NETs presentations by CommNETs members please click here

Share